Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 35, Issue 3-4, 2011, Pages 123-129

  Chellampillai, Bothiraja ^a   Pawar, Atmaram Pandurang ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Andrographolide; Oral bioavailability; Ph sensitive nanoparticles; Poly methacrylate copolymer; Wistar albino rats

Indexed keywords

ANDROGRAPHOLIDE; EUDRAGIT; NANOPARTICLE; POLOXAMER; POLY(ACRYLATE METHACRYLATE);

ACANTHACEAE; ANDROGAPHIS PANICULATA; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PH MEASUREMENT; RAT; SURFACE PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANDROGRAPHIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DITERPENES; DRUG CARRIERS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; MALE; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; POLYMETHACRYLIC ACIDS; RATS; RATS, WISTAR; SOLUBILITY;

EID: 79953790294     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-010-0016-7     Document Type: Article

References (24)

1. Bothiraja C, Shinde MB, Rajalakshmi S, Pawar AP (2009a) Evaluation of molecular pharmaceutical and in vivo properties of spray-dried isolated andrographolide-PVP. J Pharm Pharmacol 61:1465-1472
2. Bothiraja C, Pawar AP, Shaikh KS, Sher P (2009b) Eudragit EPO based nanoparticles suspension of andrographolide: in vitro and in vivo. Nanosci Nanotechnol Lett 10:156-164
3. Calabrese C, Berman SH, Babish JG, Ma X, Shinto L, Dorr M, Wells K, Wenner CA, Standish LJ (2000) A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytotherapy Res 14:333-338 (Pubitemid 30655517)
4. El-Shabouri MH (2002) Positively charged nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm 249:101-108 (Pubitemid 35333436)
5. Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E (2004) Physicochemical parameters associated with nanoparticle formation in the salting out, emulsification-diffusion and nanoprecipitation methods. Pharm Res 21:1428-1439 (Pubitemid 39149658)
6. Jaeghere FD, Allemann E, Kubel F, Galli B, Cozens R, Doelker E (2000) Oral bioavailability of a poorly water soluble HIV-I protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J Control Release 68: 291-198
7. Jayanta S (2000) Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo. Drug Discovery 7:209-213
8. Jiao Y, Ubrich N, Marchand AM, Vigneron C, Hoffman M, Lecompte T, Maincent P (2002) In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105:230-235 (Pubitemid 34084324)
9. Klipatein FA, Engert RF, Sherman WT (1983) Peroral immunization with Escherichia coli heat-labile enterotoxin delivery by microspheres. Infect Immun 39:1000-1003 (Pubitemid 13188391)
10. Kocbek P, Baumgartner S, Kristl J (2006) Preparation and evaluation of nanosuspension for enhancing the dissolution of poorly soluble drugs. Int J Pharm 312:179-186
11. Matsuda T, Kuroyanagi M, Sugiyama S, Umehara K, Ueno A, Nish K (1994) Cell differentiation-inducing diterpenes from Andrographis paniculata Nees. Chem Pharm Bull (Tokyo) 42:1216-1225 (Pubitemid 24216646)
12. McClean S, Prosser E, Meehan E, O'Malley D, Clarke N, Ramtoola Z, Brayden D (1998) Binding and uptake of biodegradable poly-DL-lactide micro-and nanoparticles in intestinal epithelia. Eur J Pharm Sci 6:153-163 (Pubitemid 28164286)
13. Morishita I, Morishita M, Takayama K, Machida Y, Nagai T (1993) Enteral insulin delivery by microspheres in 3 different formulations using Eudragit L100 and S100. Int J Pharm 91:29-37 (Pubitemid 23121398)
14. Panossian A, Hovhannisyan A, Mamikonyan G, Abrahamian H, Hambardzumyan E, Gabrielian E, Goukasova G, Wikman G, Wagner H (2000) Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine 7:351-364
15. Shenv YC, Chen CF, Chiou WF (2002) Andrographolide prevents oxygen radical production by human neutrophils: Possible mechanism(s) involved in its anti- inflammatory effect. Br J Pharmacol 135:399-406
16. Somenath R, Prajjal KS, Satyahari D (2007) Protective activity of andrographolide and arabinogalactan protein from Andrographis paniculata Nees. against ethanol-induced toxicity in mice. J Ethnopharmacol 111:13-21
17. Suo XB, Zhang H, Wang YQ (2007) HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. Biomed Chromatogr 21:730-734 (Pubitemid 47073123)
18. Thamlikitkul V, Dechatiwongse T, Theerapong S (1991) Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults. J Med Assoc Thai 74:437-442
19. Thanou M, Verhoef JC, Junginger HE (2001) Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 52:117-126 (Pubitemid 33079167)
20. ® RS or RL nanoparticles. Int J Pharm 288:169-175 (Pubitemid 39662725)
21. Zhang XF, Tan BK (2000) Antihyperglycemic and anti-oxidant properties of Andrographis paniculata in normal and diabetic rats. Clin Exp Pharmacol Physiol 27:358-363 (Pubitemid 30313434)
22. Zhao HY, Fang WY (1991) Antithrombotic effects of Andrographis paniculata Nees in preventing myocardial infarction. Chin Med J 104:770-775
23. Zhao DY, Liao KJ, Ma XY, Yan XH (2002) Computational study on the molecular inclusion of andrographolide by cyclodextrin. J Incl Phenom 43:259-264
24. Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, Cooper I (2003) Evaluation of intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem 38:233-243 (Pubitemid 36349666)